CINCINNATI, Aug. 22, 2011 /PRNewswire/ -- Prasco Laboratories, the Authorized Generics company, announced today it has signed a supply agreement with Shionogi Inc. Under the terms of the agreement, Prasco will market and distribute Nitrofurantoin Oral Suspension, the Authorized Generic version of Furadantin® Oral Suspension. Prasco intends to begin shipping product immediately in the U.S. under the Prasco label.
"Prasco is pleased to work with Shionogi to extend another of its brands, Furadantin® Oral Suspension, into our Authorized Generic product line as Nitrofurantoin Oral Suspension," said Prasco Chief Executive Officer E. Thomas Arington. "This agreement expands our relationship with Shionogi, a leading global pharmaceutical company."
Today's announcement between Shionogi and Prasco comes after another similar agreement between the two companies earlier this year.
The leader in Authorized Generics, Prasco has now brought 33 Authorized Generics to market, more than any other company. Prasco Authorized Generics are identical to brand products. Established brand companies work with Prasco to bring their brands to the generic marketplace as Authorized Generics, which offers alternatives to consumers and pharmacists.
Nitrofurantoin Oral Suspension is AB-rated, therapeutically equivalent and substitutable for the brand Furadantin® Oral Suspension. For additional important information, please click here for full prescribing information, or visit www.prasco.com
Furadantin® is a registered trademark of Shionogi Inc.
About Prasco Laboratories
Prasco is the privately held healthcare company located in Mason, Ohio, that specializes in Authorized Generics. Prasco Authorized Generics provide patients with the identical experience of a branded drug at a price that competes with generics. Prasco Authorized Generics also simplify interactions between pharmacists and consumers because they are identical to branded drugs. Moreover, Prasco Authorized Generics offer brand pharmaceutical companies a strategic lifecycle management solution.
Prasco sells its product line through the major distribution channels, and operates from a cGMP compliant, VAWD certified 160,000 sq. ft. office and distribution center including DEA-approved capabilities for Schedule II-V controlled drug products and cold-chain distribution. For more information, visit prasco.com.
|SOURCE Prasco Laboratories|
Copyright©2010 PR Newswire.
All rights reserved